bioAffinity Technologies (BIAF) Return on Capital Employed (2022 - 2026)

bioAffinity Technologies has disclosed Return on Capital Employed across 5 years of filings, most recently posting 184.46% for Q1 2026.

• In Q1 2026, Return on Capital Employed rose 18399.0% year-over-year to 184.46%; the TTM figure through Mar 2026 stood at 184.46% (up 18399.0% YoY), while the FY2025 annual figure was 181.31%, up 2873.0% from the prior year.
• Return on Capital Employed eased to 184.46% in Q1 2026, from 126.66% in the prior quarter.
• Over the last five years, Return on Capital Employed for BIAF reached as high as 33.47% in Q4 2022 and fell as low as 392.96% in Q2 2025.
• The 5-year median for Return on Capital Employed is 151.93% (2024), against an average of 169.75%.
• Annual changes were most pronounced in 2025 — Return on Capital Employed plunged 23708 bps — and 2026, when it soared 18399 bps.
• A 5-year view of Return on Capital Employed shows it stood at 33.47% in 2022, then sank by 242 bps to 114.6% in 2023, then tumbled by 128 bps to 261.19% in 2024, then jumped by 52 bps to 126.66% in 2025, then sank by 46 bps to 184.46% in 2026.
• According to Business Quant data, Return on Capital Employed over the past three periods registered 184.46%, 126.66%, and 179.34% for Q1 2026, Q4 2025, and Q3 2025 respectively.